Abstract: The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis and in particular early stages to methods of selecting a patient for therapy and to methods for monitoring disease progression in a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of PSP94 in a sample of the patient, and comparing the determined amount or concentration to a reference.

Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.

Abstract: The present invention relates to a method of assessing a female’s risk of having polycystic ovary syndrome (PCOS), a kit for use in assessing a female’s risk of having PCOS, the use of a marker combination in the assessment of a female’s risk of having PCOS, a computer system for use in a method according to the present invention as well as a computer program and a computer-readable storage medium comprising instructions, which when executed by a computer, cause the computer to carry out the method of the present invention.

Abstract: The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A9 in a sample of the patient, and comparing the determined amount or concentration to a reference.

Abstract: The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of Substance P in a sample of the patient, and comparing the determined amount or concentration to a reference.

Abstract: The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A12 in a sample of the patient, and comparing the determined amount or concentration to a reference.

Abstract: The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A8 in a sample of the patient, and comparing the determined amount or concentration to a reference.

Abstract: The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A6 in a sample of the patient, and comparing the determined amount or concentration to a reference.

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

Abstract: The present invention relates to a method for assessing whether a pregnant subject is at risk of developing preeclampsia or a preeclampsia-related condition, or not, said method comprising the steps of determining the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject, and comparing the determined amount of the biomarker to a reference. Further, the present invention relates to the in vitro use of the biomarker IGFBP-7, or of at least one detection agent which specifically binds to IGFBP-7 in a sample of a pregnant subject for assessing whether said subject is at risk of developing preeclampsia or a preeclampsia-related condition, or not. Also encompassed by the present invention is a device adapted to carry out the method of the present invention.

Abstract: The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.

Abstract: A method sets up a local control channel between a control unit for controlling a building-internal electrical component, connected to a building-internal access portal, and the access portal, by authenticating the control unit against a building-external authentication server via a building-external communication network; transmitting a network address of the building-internal access portal using the building-external authentication server to the control unit upon successful authentication of the control unit against the building-external authentication server via the building-external communication network; transmitting an access authorization for the building-internal access portal to the control unit using the building-external authentication server via the building-external communication network upon successful authentication of the control unit against the building-external authentication server via the building-external communication network; and setting up the local control channel between the control

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

Abstract: An access portal for controlling communication between a building-external communication server of a building-external communication network and a building-internal communication entity of a building-internal communication network includes: a memory for storing authentication data for initiating a communication connection to the communication server; a first communication interface for establishing communication with the building-external communication server using the stored authentication data, wherein the first communication interface is configured to monitor the communication connection to the building-external communication server and, in the event of a fault in the communication connection, to generate a fault message; and a second communication interface for communicating with the communication entity, wherein the second communication interface is configured to send the stored authentication data to the building-internal communication entity in response to receiving the fault message in order to initia

Abstract: Diagnostic methods and tools relating to diagnosing whether a pregnant subject is at risk for developing preeclampsia and/or early-onset preeclampsia within a short period of time. The methods include determining the amounts of the biomarkers sFlt-1 or Endoglin and PIGF in a first and a second sample of said subject, said first sample being obtained prior to said second sample; calculating a first ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the first sample, and a second ratio from the amounts of sFlt-1 or Endoglin and PIGF determined in the second sample; and comparing the value of the first and the second ratio, whereby a subject being at risk for developing preeclampsia within a short period of time is diagnosed if the value of the second ratio is increased compared to the value of the first ratio by a factor of at least about 3.

Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.

Abstract: A method for controlling at least one device in at least one building includes: selectively transferring, by a control system comprising a server and a number of gateways, at least one application from the server to a particular gateway or from a particular gateway to the server based on at least one transfer rule; and controlling, by the control system, the at least one device via the at least one application.

Abstract: The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.

Abstract: A method for controlling at least one device in at least one building includes: selectively transferring, by a control system comprising a server and a number of gateways, at least one application from the server to a particular gateway or from a particular gateway to the server based on at least one transfer rule; and controlling, by the control system, the at least one device via the at least one application.

Abstract: A method sets up a local control channel between a control unit for controlling a building-internal electrical component, connected to a building-internal access portal, and the access portal, by authenticating the control unit against a building-external authentication server via a building-external communication network; transmitting a network address of the building-internal access portal using the building-external authentication server to the control unit upon successful authentication of the control unit against the building-external authentication server via the building-external communication network; transmitting an access authorization for the building-internal access portal to the control unit using the building-external authentication server via the building-external communication network upon successful authentication of the control unit against the building-external authentication server via the building-external communication network; and setting up the local control channel between the control